Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of Follicular Thyroid Carcinoma (FTC)
Authors' conclusion
The RAIT can provide a CSS advantage for patients with wi-FTC who with N1-stage or M1-stage disease.
Study context
- Population
- Patients with minimally invasive FTC (mi-FTC), encapsulated angioinvasive FTC (ea-FTC) or widely invasive FTC (wi-FTC), 2000–2020, Surveillance, Epidemiology, and End Results database
- Exposure
- Radioactive iodine therapy (RAIT) vs no RAIT across WHO FTC subtypes
- mi-FTCn = 2,433
- ea-FTCn = 216
- wi-FTCn = 554
- Outcome
- CSS, compared among the 3 FTC subtypes before and after propensity score matching (PSM)
Methodological detailsSEER database, propensity score matching
- SEER database
- Propensity score matching
Main finding
As reported in the abstract
CSS, RAIT vs no RAIT (Cox regression, PSM cohorts)
RAIT vs No-RAITHazard ratio (95% CI)P value
mi-FTC PSM cohort
1.21(.46-3.18)
P = 0.705wi-FTC PSM cohort
0.56(.35-1.08)
P = 0.086- Patients with mi-FTC or ea-FTC had similar cancer-specific survival (CSS)
- P = 0.805
- CSS of mi-FTC and ea-FTC better than wi-FTC
- P < 0.001; P = .021
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| CSS, RAITvs no RAIT, subgroup wi-FTC with N1 stageSubgroup analysis | 0.44 (.20-.99) | P = 0.018 | |
| CSS, RAITvs no RAIT, subgroup wi-FTC with M1 stageSubgroup analysis | 0.25 (.11-.53) | P < 0.001 | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC. J Clin Endocrinol Metab. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →